Trial reportQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2009
Predicting EQ-5D utility scores from the 25-item National Eye Institute Vision Function Questionnaire (NEI-VFQ 25) in patients with age-related macular degeneration.
Trial report in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Trial
- Mapping Health State Utility from Disease-Specific Measures in Spinal Muscular Atrophy and Paroxysmal Nocturnal Hemoglobinuria.PharmacoEconomics · 2026Article
- Measuring the quality of life of patients with diabetic retinopathy in northern India: a comparison of generic and vision specific instruments.Health and quality of life outcomes · 2025Article
- Developing mapping algorithms to predict EQ-5D health utility values from Bath Ankylosing Spondylitis Disease Activity Index and Bath Ankylosing Spondylitis Functional Index among patients with Ankylosing Spondylitis.Health and quality of life outcomes · 2024Article
- Cost-effectiveness of the anti-vascular endothelial growth factor intravitreal injection and panretinal photocoagulation for patients with proliferative diabetic retinopathy in South Korea.BMC health services research · 2023Article
- Predictors of problems reported on the EQ-5D-3L dimensions among people with impaired vision in northern Portugal.Health and quality of life outcomes · 2022Observational
- Patient-Reported Health-Related Quality of Life in Individuals with Inherited Retinal Diseases.Ophthalmology science · 2022Article
- Stress and vision-related quality of life in acute and chronic central serous chorioretinopathy.BMC ophthalmology · 2020Article
- Mapping the Positive and Negative Syndrome Scale scores to EQ-5D-5L and SF-6D utility scores in patients with schizophrenia.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2019Article
- A comparison of the responsiveness of EQ-5D-5L and the QOLIE-31P and mapping of QOLIE-31P to EQ-5D-5L in epilepsy.The European journal of health economics : HEPAC : health economics in prevention and care · 2018Article
- Mapping the Paediatric Quality of Life Inventory (PedsQL™) Generic Core Scales onto the Child Health Utility Index-9 Dimension (CHU-9D) Score for Economic Evaluation in Children.PharmacoEconomics · 2018Article
- Mapping CHU9D Utility Scores from the PedsQLPharmacoEconomics · 2017Article
- Generic and disease-specific estimates of quality of life in macular degeneration: mapping the MacDQoL onto the EQ-5D-3L.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2016Article
- Mapping health assessment questionnaire disability index (HAQ-DI) score, pain visual analog scale (VAS), and disease activity score in 28 joints (DAS28) onto the EuroQol-5D (EQ-5D) utility score with the KORean Observational study Network for Arthritis (KORONA) registry data.Rheumatology international · 2016Observational
- The MAPS Reporting Statement for Studies Mapping onto Generic Preference-Based Outcome Measures: Explanation and Elaboration.PharmacoEconomics · 2015Article
- Predicting health utilities for children with autism spectrum disorders.Autism research : official journal of the International Society for Autism Research · 2014Article
- From KIDSCREEN-10 to CHU9D: creating a unique mapping algorithm for application in economic evaluation.Health and quality of life outcomes · 2014Article
- Vision related quality of life in patients with keratoconus.Journal of ophthalmology · 2014Article
- Responsiveness of the EQ-5D to the effects of low vision rehabilitation.Optometry and vision science : official publication of the American Academy of Optometry · 2013Article
- Evaluation of content on EQ-5D as compared to disease-specific utility measures.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIn this study, we explored different statistical approaches to identify the best algorithm to predict EQ-5D utility scores from the NEI-VFQ 25 in patients with age-related macular degeneration (AMD).
methodsOrdinary least squares (OLS), Tobit, and censored least absolute deviation (CLAD) approaches were compared using cross-sectional data (primary dataset, n = 151) at screening from a phase I/II clinical trial in patients with AMD. Three models were specified in this study: full (includes all 12 dimensions of the NEI-VFQ 25), short (includes only the general health dimension and the composite score), and reduced model (using stepwise regression). To evaluate the predictive accuracy of the models, the mean absolute prediction error (MAPE), mean error, and root means squared error were calculated using in-sample cross-validation (within the primary dataset) and out-of-sample validation using an independent dataset (n = 393). The model that provided the lowest prediction errors was chosen as the best model.
resultsIn-sample cross-validation and out-of-sample validation consistently demonstrated that, compared to other approaches, heteroscedasticity-adjusted OLS produced the lowest MAPE (mean values were 0.1400, 0.1593, respectively) for the full model, while CLAD performed best for the short and reduced models (mean values were 0.1299, 0.1483, respectively). The normality and homoscedasticity assumptions of both OLS and Tobit were rejected. CLAD, however, can accommodate these particular violations.
conclusionsThe CLAD-short model is recommended for producing the EQ-5D utility scores when only the NEI-VFQ 25 data are available.
Indexed as
Identifiers
19543808What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.